JPM-TMT Announces Contract Award for Advanced Development of Broad-spectrum Influenza Drug

The Department of Defense’s (DOD) Joint Project Manager Transformational Medical Technologies (JPM-TMT) awarded a $138.5M contract to MediVector, Inc. to further develop Favipiravir (T-705), a broad–spectrum therapeutic against multiple influenza viruses, including the 2009 H1N1 pandemic virus and drug resistant influenza strains. The contract will help bolster the protection of the Joint Forces against naturally occurring pandemic influenza and/or biologically engineered flu viruses.

Read More.